Association of MicroRNA-33a Molecular Signature with Non-Small Cell Lung Cancer Diagnosis and Prognosis After Chemotherapy

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2017 Feb 1

PMID 28141816

Citations 18

Authors

Li-Kun Hou

Yu-Shui Ma

Yang Han

Gai-Xia Lu

Pei Luo

Zheng-Yan Chang

Ru-Ting Xie

Hui-Qiong Yang

Li Chai

Ming-Xiang Cai

Ting-Miao Wu

Fei Yu

Shan-shan Qin

Zhong-Wei Lv

Chun-Yan Wu

Da Fu

Affiliations

Soon will be listed here.

Abstract

Objective: This study aims to explore the expression pattern and prognostic significance of miR-33a in non-small cell lung cancer (NSCLC) treated with adjuvant chemotherapy.

Methods: MiR-33aexpression in NSCLC was analyzed in silico using the GEO database and was subsequently confirmed by quantitative RT-PCR in 147 NSCLC biopsies. Among these, 32 of these biopsies were paired with adjacent non-neoplastic tissues. The survival analysis of NSCLC by Kaplan-Meier estimates was stratified based on miR-33a expression. In addition, multivariate survival analysis in corresponding groups of NSCLC patients was conducted by Cox proportional hazards regression model.

Results: The in silico analysis of miR-33a expression in NSCLC resulted to its down-regulation in different tumor types. The expression level of miR-33a was lower in each grade of NSCLC tumor biopsies than in normal lung tissues. Univariate and multivariate survival analysis further established that low miR-33a expression was an important risk factor for overall survival and disease free survival in NSCLC patients.

Conclusion: Our study implied that miR-33a expression levels may have an essential role in NSCLC progression, and could act as a specific and sensitive biomarker for NSCLC patients who have undergone adjuvant chemotherapy.

Citing Articles

Abnormal Gene Expression Regulation Mechanism of Myeloid Cell Nuclear Differentiation Antigen in Lung Adenocarcinoma.

Tang Z, Wang L, Bajinka O, Wu G, Tan Y Biology (Basel). 2022; 11(7).

PMID: 36101427 PMC: 9312870. DOI: 10.3390/biology11071047.

APE1 controls DICER1 expression in NSCLC through miR-33a and miR-130b.

Antoniali G, Dalla E, Mangiapane G, Zhao X, Jing X, Cheng Y Cell Mol Life Sci. 2022; 79(8):446.

PMID: 35876890 PMC: 9314295. DOI: 10.1007/s00018-022-04443-7.

Identification of three miRNAs signature as a prognostic biomarker in breast cancer using bioinformatics analysis.

Sang M, Li A, Wang X, Chen C, Liu K, Bai L Transl Cancer Res. 2022; 9(3):1884-1893.

PMID: 35117535 PMC: 8798573. DOI: 10.21037/tcr.2020.02.21.

Clinical Value and Potential Mechanism of miRNA-33a-5p in Lung Squamous Cell Carcinoma.

Wang X, Chen S, Chen G, Zhou H, Gan T, Zeng J Anal Cell Pathol (Amst). 2021; 2021:6614331.

PMID: 34888137 PMC: 8649614. DOI: 10.1155/2021/6614331.

Overexpression of microRNA-124-5p sensitizes non-small cell lung cancer cells to treatment with 5-fluorouracil via AEG-1 regulation.

Tan X, Zhang C, Gao W, Sun B, Jiang B, Song P Oncol Lett. 2020; 21(1):5.

PMID: 33240411 PMC: 7681228. DOI: 10.3892/ol.2020.12266.

References

Ibrahim A, Weirauch U, Thomas M, Grunweller A, Hartmann R, Aigner A . MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res. 2011; 71(15):5214-24. DOI: 10.1158/0008-5472.CAN-10-4645. View

Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M . Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9(3):189-98. DOI: 10.1016/j.ccr.2006.01.025. View

Zhou Y, Huang Z, Wu S, Zang X, Liu M, Shi J . miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST. J Exp Clin Cancer Res. 2014; 33:12. PMC: 3974149. DOI: 10.1186/1756-9966-33-12. View

Cykert S, Dilworth-Anderson P, Monroe M, Walker P, McGuire F, Corbie-Smith G . Factors associated with decisions to undergo surgery among patients with newly diagnosed early-stage lung cancer. JAMA. 2010; 303(23):2368-76. PMC: 4152904. DOI: 10.1001/jama.2010.793. View

Neoptolemos J, Stocken D, Friess H, Bassi C, Dunn J, Hickey H . A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004; 350(12):1200-10. DOI: 10.1056/NEJMoa032295. View

Wheeler D, Church D, Lash A, Leipe D, Madden T, Pontius J . Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 2000; 29(1):11-6. PMC: 29800. DOI: 10.1093/nar/29.1.11. View

Zhang C, Zhang Y, Ding W, Lin Y, Huang Z, Luo Q . MiR-33a suppresses breast cancer cell proliferation and metastasis by targeting ADAM9 and ROS1. Protein Cell. 2015; 6(12):881-9. PMC: 4656205. DOI: 10.1007/s13238-015-0223-8. View

He L, Hannon G . MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5(7):522-31. DOI: 10.1038/nrg1379. View

Edge S, Compton C . The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17(6):1471-4. DOI: 10.1245/s10434-010-0985-4. View

10.

Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K . Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18(10):997-1006. DOI: 10.1038/cr.2008.282. View

11.

Masters G, Temin S, Azzoli C, Giaccone G, Baker Jr S, Brahmer J . Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015; 33(30):3488-515. PMC: 5019421. DOI: 10.1200/JCO.2015.62.1342. View

12.

Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S . A MicroRNA targeting dicer for metastasis control. Cell. 2010; 141(7):1195-207. DOI: 10.1016/j.cell.2010.05.017. View

13.

Camps C, Buffa F, Colella S, Moore J, Sotiriou C, Sheldon H . hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res. 2008; 14(5):1340-8. DOI: 10.1158/1078-0432.CCR-07-1755. View

14.

Yu S, Chen H, Chang G, Chen C, Chen H, Singh S . MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 2008; 13(1):48-57. DOI: 10.1016/j.ccr.2007.12.008. View

15.

Zen K, Zhang C . Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev. 2012; 32(2):326-48. DOI: 10.1002/med.20215. View

16.

Wang R, Wang Z, Yang J, Pan X, De W, Chen L . MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene. 2011; 30(23):2644-58. DOI: 10.1038/onc.2010.642. View

17.

Yates L, Norbury C, Gilbert R . The long and short of microRNA. Cell. 2013; 153(3):516-9. DOI: 10.1016/j.cell.2013.04.003. View

18.

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S . American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25(33):5287-312. DOI: 10.1200/JCO.2007.14.2364. View

19.

Zhou J, Xu D, Xie H, Tang J, Liu R, Li J . miR-33a functions as a tumor suppressor in melanoma by targeting HIF-1α. Cancer Biol Ther. 2015; 16(6):846-55. PMC: 4622471. DOI: 10.1080/15384047.2015.1030545. View

20.

Reck M, Heigener D, Mok T, Soria J, Rabe K . Management of non-small-cell lung cancer: recent developments. Lancet. 2013; 382(9893):709-19. DOI: 10.1016/S0140-6736(13)61502-0. View